Product Description
Mechanisms of Action: Cytokine Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Algeria | Australia | Belgium | Bosnia | Brazil | Bulgaria | Canada | China | Colombia | Croatia | Czech | Ecuador | Egypt | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Korea | Latvia | Lithuania | Mexico | Morocco | New Zealand | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Spain | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: None
Company: POLYSAN Scientific & Technological Pharmaceutical Company
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Kazakhstan, Russia
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Cholestasis, Intrahepatic|Craniocerebral Trauma|Head Injuries, Closed|Stroke
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06183242 |
RXA-II-III-Chol-2022 | P3 |
Recruiting |
Cholestasis, Intrahepatic |
2025-05-01 |
2023-12-28 |
Primary Endpoints |
|
NCT05935787 |
CTF-III-SR-2022 | P3 |
Completed |
Stroke |
2024-08-01 |
31% |
2025-08-16 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT04631484 |
MITRA | P3 |
Completed |
Craniocerebral Trauma|Head Injuries, Closed |
2024-05-07 |
15% |
2024-10-02 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/12/2026 |
News Article |
ProQR Announces Year End 2025 Operating and Financial Results |
|
03/03/2026 |
News Article |
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference |
|
02/09/2026 |
News Article |
ProQR Announces Planned Changes to Board Composition |
|
01/08/2026 |
News Article |
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook |